X

Stay Connected

Sign Up for Updates

 
We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New analysis: More than half of patients’ out-of-pocket spending for brand medicines is based on full list price

By Holly Campbell  |    March 29, 2017
More than half of commercially insured patients’ out-of-pocket spending for brand medicines is based on full list prices, according to a new analysis from Amundsen Consulting, a division of...   Read More

Resources for understanding the dangers of drug importation

By Nicole Longo  |    March 28, 2017
Recent proposals to allow drug importation from other countries are dangerous for patients and the U.S. drug supply chain. To better understand how these importation schemes could negatively affect...   Read More

ICYMI: Survey highlights key barriers limiting number and scale of new approaches to paying for medicines

By Michelle Drozd  |    March 27, 2017
In recent years we have seen remarkable scientific breakthroughs in the discovery of new therapies to treat some of the most challenging diseases faced by patients. These groundbreaking medicines...   Read More

Medicare Monday: A discussion on affordability and access to medicines

By Nicole Longo  |    March 27, 2017
In case you missed it, the American Society on Aging held its annual conference last week in Chicago, IL, where Lori Reilly, PhRMA executive vice president of policy, research & membership, spoke...   Read More

17 years (and more) of medical discoveries

By Priscilla VanderVeer  |    March 24, 2017
Someone asked me recently if donated kidneys last forever. It’s been 17 years and a few days since I received one, which has lasted 17 years longer than I thought it would. That may not be forever,...   Read More

ICYMI: What the experts are saying about importation

By Allyson Funk  |    March 23, 2017
Voices throughout the U.S. and Canadian health care systems have raised concerns about proposed large-scale drug importation schemes. Former government officials, pharmacy groups and experts have...   Read More

Guest Post: The importance of a modern FDA in drug discovery

By Guest Contributor  |    March 22, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Medicare Monday: Billing code basics for biologics in Part B

By Allyson Funk  |    March 20, 2017
We’ve explored the Centers for Medicare & Medicaid Services’ (CMS) flawed policy for reimbursing biologic and biosimilar products before. Today, we’re exploring how proposals from MedPAC would build...   Read More

How drug importation schemes could increase U.S. law enforcement burdens

By Allyson Funk  |    March 16, 2017
In recent weeks, we’ve explored some of the dangers of importation for patients and how medicines purchased online can be fake. But what would importation schemes mean for U.S. law enforcement?   Read More

Medicare Monday: A closer look at Part B spending

By Nicole Longo  |    March 13, 2017
Earlier this month, MedPAC discussed Part B drug spending growth but neglected to put this information in the context of overall program spending. Spending on Part B medicines continues to be a small...   Read More

Stakeholders Agree: Modernize the legal framework to support move to value-driven health care

By Michelle Drozd  |    March 6, 2017
Modernizing certain laws and regulations to support the move to value-driven health care is an important step in moving our health care system forward. As part of PhRMA’s proactive policy solutions,...   Read More

Medicare Monday: New study further confirms increased use of generics after Part D

By Nicole Longo  |    March 6, 2017
On Medicare Monday, we’ve talked a lot about how things have changed since 2006 and the implementation of Part D. We’ve looked at how Part D costs less than originally projected, how premiums have...   Read More

Guest Post: Room for optimism in ALS research

By Guest Contributor  |    March 3, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Guest Post: Debra of America on Epidermolysis Bullosa

By Guest Contributor  |    March 3, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Guest Post: A Cure for Ellie on Leukodystrophy-LBSL

By Guest Contributor  |    March 2, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

Case Study: How one online pharmacy knowingly endangered U.S. consumers

By Nicole Longo  |    March 2, 2017
We recently looked at what actually happens when a patient orders a medicine through an online Canadian pharmacy and how the product delivered may not be what the patient ordered. Today, we’re taking...   Read More

Guest Post: Epilepsy Foundation on rare diseases

By Guest Contributor  |    March 1, 2017
Conversations and healthy debate about issues facing our industry and the health care system are critical to addressing some of today’s challenges and opportunities. The Catalyst welcomes guest...   Read More

How innovative medicines are benefiting countries across the globe

By Mark Grayson  |    March 1, 2017
It is important to look at costs across health care systems to fully understand how life-changing medicines are providing a more sustainable path forward. Across the globe, medicines are allowing...   Read More

Search the Catalyst

View Posts by Topic

see all

View Posts by Contributor

View Posts by Date

see all

Subscribe to Email Updates